cancer immune therapy

Activartis Has Received European Orphan Drug Designation for a Cancer Immune Therapy
Mar 13, 2013
Activartis has received European orphan drug designation for a cancer immune therapy, AV0113, for use in the treatment of glioma. AV0113, which was developed against every type of cancer, is based on a procedure where the immune system ...

Tags: orphan drug, cancer immune therapy